Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

被引:72
作者
Buddhari, Darunee [1 ]
Aldstadt, Jared [2 ]
Endy, Timothy P. [3 ]
Srikiatkhachorn, Anon [4 ]
Thaisomboonsuk, Butsaya [1 ]
Klungthong, Chonticha [1 ]
Nisalak, Ananda [1 ]
Khuntirat, Benjawan [1 ]
Jarman, Richard G. [5 ]
Fernandez, Stefan [1 ]
Thomas, Stephen J. [5 ]
Scott, Thomas W. [6 ,7 ]
Rothman, Alan L. [8 ]
Yoon, In-Kyu [1 ]
机构
[1] Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand
[2] SUNY Buffalo, Dept Geog, Buffalo, NY 14260 USA
[3] SUNY Syracuse, Dept Infect Dis, Syracuse, NY USA
[4] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA
[5] Walter Reed Army Inst Res, Viral Dis Branch, Silver Spring, MD USA
[6] Univ Calif Davis, Dept Entomol & Nematol, Davis, CA 95616 USA
[7] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA
[8] Univ Rhode Isl, Inst Immunol & Informat, Providence, RI 02908 USA
来源
PLOS NEGLECTED TROPICAL DISEASES | 2014年 / 8卷 / 10期
基金
比尔及梅琳达.盖茨基金会; 美国国家卫生研究院;
关键词
DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; MOLECULAR-BIOLOGY; ENVELOPE PROTEIN; TIME-INTERVAL; T-CELLS; VILLAGES; COHORT; TRANSMISSION; CHILDREN;
D O I
10.1371/journal.pntd.0003230
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Long-term homologous and temporary heterologous protection from dengue virus (DENV) infection may be mediated by neutralizing antibodies. However, neutralizing antibody titers (NTs) have not been clearly associated with protection from infection. Methodology/Principal Findings: Data from two geographic cluster studies conducted in Kamphaeng Phet, Thailand were used for this analysis. In the first study (2004-2007), cluster investigations of 100-meter radius were triggered by DENV-infected index cases from a concurrent prospective cohort. Subjects between 6 months and 15 years old were evaluated for DENV infection at days 0 and 15 by DENV PCR and IgM ELISA. In the second study (2009-2012), clusters of 200-meter radius were triggered by DENV-infected index cases admitted to the provincial hospital. Subjects of any age >= 6 months were evaluated for DENV infection at days 0 and 14. In both studies, subjects who were DENV PCR positive at day 14/15 were considered to have been "susceptible'' on day 0. Comparison subjects from houses in which someone had documented DENV infection, but the subject remained DENV negative at days 0 and 14/15, were considered "non-susceptible.'' Day 0 samples were presumed to be from just before virus exposure, and underwent plaque reduction neutralization testing (PRNT). Seventeen "susceptible'' (six DENV-1, five DENV-2, and six DENV-4), and 32 "non-susceptible'' (13 exposed to DENV-1, 10 DENV-2, and 9 DENV-4) subjects were evaluated. Comparing subjects exposed to the same serotype, receiver operating characteristic (ROC) curves identified homotypic PRNT titers of 11, 323 and 16 for DENV-1, -2 and -4, respectively, to differentiate "susceptible'' from "non-susceptible'' subjects. Conclusions/Significance: PRNT titers were associated with protection from infection by DENV-1, -2 and -4. Protective NTs appeared to be serotype-dependent and may be higher for DENV-2 than other serotypes. These findings are relevant for both dengue epidemiology studies and vaccine development efforts.
引用
收藏
页数:10
相关论文
共 38 条
[21]   Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages [J].
Mammen, Mammen P., Jr. ;
Pimgate, Chusak ;
Koenraadt, Constantianus J. M. ;
Rothman, Alan L. ;
Aldstadt, Jared ;
Nisalak, Ananda ;
Jarman, Richard G. ;
Jones, James W. ;
Srikiatkhachorn, Anon ;
Ypil-Butac, Charity Ann ;
Getis, Arthur ;
Thammapalo, Suwich ;
Morrison, Amy C. ;
Libraty, Daniel H. ;
Green, Sharone ;
Scott, Thomas W. .
PLOS MEDICINE, 2008, 5 (11) :1605-1616
[22]   RETRACTED: Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity (Retracted article. See vol. 112, pg. E2738, 2015) [J].
Messer, William B. ;
de Alwis, Ruklanthi ;
Yount, Boyd L. ;
Royal, Scott R. ;
Huynh, Jeremy P. ;
Smith, Scott A. ;
Crowe, James E., Jr. ;
Doranz, Benjamin J. ;
Kahle, Kristen M. ;
Pfaff, Jennifer M. ;
White, Laura J. ;
Sariol, Carlos A. ;
de Silva, Aravinda M. ;
Baric, Ralph S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (05) :1939-1944
[23]   Dengue Virus Infection-Enhancing Activity in Serum Samples with Neutralizing Activity as Determined by Using FcγR-Expressing Cells [J].
Moi, Meng Ling ;
Lim, Chang-Kweng ;
Chua, Kaw Bing ;
Takasaki, Tomohiko ;
Kurane, Ichiro .
PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (02)
[24]   Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year [J].
Montoya, Magelda ;
Gresh, Lionel ;
Carlos Mercado, Juan ;
Williams, Katherine L. ;
Jose Vargas, Maria ;
Gutierrez, Gamaliel ;
Kuan, Guillermina ;
Gordon, Aubree ;
Balmaseda, Angel ;
Harris, Eva .
PLOS NEGLECTED TROPICAL DISEASES, 2013, 7 (08)
[25]  
Pepe MS, 2009, STATA J, V9, P1
[26]   Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis [J].
Rainwater-Lovett, Kaitlin ;
Rodriguez-Barraquer, Isabel ;
Cummings, Derek A. T. ;
Lessler, Justin .
BMC INFECTIOUS DISEASES, 2012, 12
[27]   Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity [J].
Reich, Nicholas G. ;
Shrestha, Sourya ;
King, Aaron A. ;
Rohani, Pejman ;
Lessler, Justin ;
Kalayanarooj, Siripen ;
Yoon, In-Kyu ;
Gibbons, Robert V. ;
Burke, Donald S. ;
Cummings, Derek A. T. .
JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2013, 10 (86)
[28]   pROC: an open-source package for R and S plus to analyze and compare ROC curves [J].
Robin, Xavier ;
Turck, Natacha ;
Hainard, Alexandre ;
Tiberti, Natalia ;
Lisacek, Frederique ;
Sanchez, Jean-Charles ;
Mueller, Markus .
BMC BIOINFORMATICS, 2011, 12
[29]  
RUSSELL PK, 1967, J IMMUNOL, V99, P285
[30]   Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial [J].
Sabchareon, Arunee ;
Wallace, Derek ;
Sirivichayakul, Chukiat ;
Limkittikul, Kriengsak ;
Chanthavanich, Pornthep ;
Suvannadabba, Saravudh ;
Jiwariyavej, Vithaya ;
Dulyachai, Wut ;
Pengsaa, Krisana ;
Wartel, T. Anh ;
Moureau, Annick ;
Saville, Melanie ;
Bouckenooghe, Alain ;
Viviani, Simonetta ;
Tornieporth, Nadia G. ;
Lang, Jean .
LANCET, 2012, 380 (9853) :1559-1567